Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Uridine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Uridine | DRUG | - |
Inclusion Criteria: 1. DSM-IV-TR diagnosis of Bipolar I Depression 2. 18 to 65 years of age, inclusive 3. Depressive phase, as measured by MADRS greater than or equal to 20 at Screening and Day1 4. Duration of current depressive episode of at least four weeks by Day 1 5. Competent to give informed ...
Uridine is an investigational small molecule being studied for the treatment of Bipolar Depression. It is being developed by Repligen Corporation (NASDAQ: RGEN). The drug is currently in Phase 2 clinical development, meaning it is still being tested in clinical trials and is not yet approved for use.
The specific molecular target of Uridine has not been disclosed. It is a small molecule being investigated for its potential therapeutic effects in Bipolar Depression. The drug is being developed by Repligen Corporation (NASDAQ: RGEN) and is currently in Phase 2 clinical trials.
Uridine is being developed by Repligen Corporation, a biopharmaceutical company traded on NASDAQ under the ticker symbol RGEN. The company is conducting clinical research to evaluate the drug as a potential treatment for Bipolar Depression. Uridine is currently in Phase 2 clinical development.
Uridine is in Phase 2 clinical development for the treatment of Bipolar Depression. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 2 clinical trial to assess its safety and efficacy in patients with Bipolar I Depression.
Uridine has one completed Phase 2 clinical trial registered under NCT00322764, titled "Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression." The trial enrolled 80 participants in the United States and was a randomized, double-blind study. The drug is being developed by Repligen Corporation (NASDAQ: RGEN).
Yes, Uridine is also known as RG2417. The Phase 2 clinical trial NCT00322764, which evaluated the drug for Bipolar I Depression, used the name RG2417 in its title. Repligen Corporation (NASDAQ: RGEN) is the developer of this investigational small molecule.